Name: hVIVO’s unique model, and why as a world leader in human challenge trials it’s becoming a critical component of drug development
Uploaded: 2023-01-25T07:55:07.534434+00:00
Duration: 647 s
Channel: Vox Markets
Description: hVIVO’s unique model, and why as a world leader in human challenge trials it’s becoming a critical component of drug development

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/005/662/005662/video_Vt30niW.mp4#t=395

Vox Markets

hVIVO’s unique model, and why as a world leader in human challenge trials  it’s becoming a critical component of drug development

Highlights of the trading update, and drivers behind an exceptional ahead- of-expectations performance

Market drivers behind the company’s strong performance, including a  growing realisation among drug developers of the value of human challenge  trials

Delivering the huge order backlog and growing the pipeline of potential new deals, and the coming launch of new challenge models

Discusses the recent Venn Life Sciences consultancy contract win

Using strengthening cash generation to start paying a dividend alongside  continued investment in growth

Vox Markets speaks to Mo Khan, chief executive of fast-growing clinical research specialist hVIVO, about the factors behind an expectation-beating year, and how rising awareness of its unique human challenge model points to major growth ahead.

0:29 Highlights of the trading update, and drivers behind an exceptional ahead-of-expectations performance
2:04 Market drivers behind the company’s strong performance, including a growing realisation among drug developers of the value of human challenge trials
3:59 Delivering the huge order backlog and growing the pipeline of potential new deals, and the coming launch of new challenge models
6:35 hVIVO’s unique model, and why as a world leader in human challenge trials it’s becoming a critical component of drug development
8:04 Discusses the recent Venn Life Sciences consultancy contract win
9:02 Using strengthening cash generation to start paying a dividend alongside continued investment in growth

Vox Markets speaks to Mo Khan, chief executive of fast-growing clinical research specialist hVIVO, about the factors behind an expectation-beating year, and how rising awareness of its unique human challenge model points to major growth ahead.0:29 Highlights of the trading update, and drivers behind an exceptional ahead-of-expectations performance 2:04 Market drivers behind the company’s strong performance, including a growing realisation among drug developers of the value of human challenge trials 3:59 Delivering the huge order backlog and growing the pipeline of potential new deals, and the coming launch of new challenge models 6:35 hVIVO’s unique model, and why as a world leader in human challenge trials it’s becoming a critical component of drug development 8:04 Discusses the recent Venn Life Sciences consultancy contract win 9:02 Using strengthening cash generation to start paying a dividend alongside continued investment in growth

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/005/662/005662/video_Vt30niW.mp4